FDA Greenlights First Heart Drug for Teens With Rare Condition

On September 30, 2026, the U.S. Food and Drug Administration approved Camzyos (mavacamten) capsules for children with symptomatic obstructive hypertrophic cardiomyopathy, making it the first heart drug for teens approved to improve functional capacity and symptoms in this rare inherited heart condition. The expanded label covers adults and pediatric patients weighing at least 30 kilograms, or about 66 pounds. The drug had previously been cleared only for adults when it first reached the market in 2022, according to the FDA.

Obstructive hypertrophic cardiomyopathy, often shortened to oHCM, is a genetic condition that causes the heart muscle to grow abnormally thick. That thickening can narrow the left ventricular outflow tract, the passage blood must cross to leave the heart and reach the rest of the body. Patients can develop shortness of breath, crushing fatigue, and abnormal heart rhythms that can turn life-threatening. Hypertrophic cardiomyopathy is also one of the most common medical causes of sudden cardiac death in young athletes, which is why any new treatment option for adolescents lands hard with teen sports families.

Camzyos belongs to a class called cardiac myosin inhibitors. Rather than simply lowering blood pressure or slowing the heart rate, it dials down the over-contracting heart muscle itself, easing the obstruction and lowering the pressure inside the heart. That targeted mechanism is what separates it from every older option kids have been stuck with until now.

Why the first heart drug for teens fills a real gap

Before this approval, pediatric cardiologists had no medicine specifically cleared for children with the condition. Treatment relied on beta-blockers, calcium channel blockers, and disopyramide, with dosing and expectations largely extrapolated from adult studies, according to HCPLive. For families navigating a serious cardiovascular disease during the middle of childhood development, that off-label guesswork added anxiety to an already frightening diagnosis.

"This approval represents an important change in the treatment landscape because it gives pediatric cardiologists for the first time a therapy that directly targets the underlying hypercontractility," said Dr. Joseph Rossano, chief of cardiology at Children's Hospital of Philadelphia and principal investigator of the pediatric trial, in a statement carried by HCPLive. Bristol Myers Squibb, which makes the drug, said the expanded label gives Camzyos the broadest indication of any drug in its class.

What the pediatric trial actually showed

The September 2026 approval rests on a phase 3 study known as SCOUT-HCM, a randomized, double-blind, placebo-controlled trial run at centers around the world. It enrolled 44 adolescents between the ages of 12 and 18 with symptomatic disease, assigning them to receive Camzyos or a placebo once daily for 28 weeks, according to the FDA. Results were published in the New England Journal of Medicine.

At week 28, patients on the drug showed a reduction in the pressure gradient across the obstructed outflow tract of roughly 48 millimeters of mercury more than patients on placebo, a statistically significant result that met the trial's primary endpoint. None of the treated patients saw their heart's pumping function, measured as ejection fraction, fall below the safety threshold of 50 percent. No patient stopped treatment because of side effects, and serious adverse events occurred at similar low rates in both groups, reported Becker's Hospital Review. Because reduced obstruction in adults has been tied to better day-to-day functioning and fewer symptoms, regulators expect the same benefit for younger patients.

Longer-term evidence adds confidence: five-year follow-up data from adults presented at the European Society of Cardiology Congress in Munich during 2026 showed sustained reductions in the obstruction and lasting improvements in symptom class, according to HCPLive. That kind of durability matters for a condition families live with for life.

The serious fine print every family should know

This is not a casual prescription. Camzyos carries a boxed warning for the risk of heart failure, and it is available only through a restricted safety program that requires echocardiogram monitoring and careful management of drug interactions, according to Becker's Hospital Review. Dizziness and fainting occurred in more than one in twenty patients in the trial and were more common in the group receiving the drug than in the placebo group.

The approval also does not rewrite the underlying genetics. The drug eases the obstruction and symptoms, but the thickened heart muscle and the family history behind it remain. Kids on Camzyos will still need ongoing cardiology follow-up, and because the safety program adds logistical hurdles, families should expect coordination with a specialized center rather than a quick pharmacy pickup. For a broader look at how everyday habits intersect with heart health, see our health topic page, and for more on diet's role in cardiac risk, read how small daily portions of ultra-processed food raise heart risk.

The practical takeaway is straightforward. With the first heart drug for teens now cleared for patients as young as twelve, this approval opens a conversation worth having with a pediatric cardiologist right now. After years when the pediatric playbook was borrowed from adult data, young patients finally have a therapy that was tested on people their age, and that changes the odds in a condition where every bit of breathing room counts.